A biologics client needed to transition five therapies from PHSA Section 351 to Section 361. We redesigned facilities, validated equipment, remediated QMS gaps, updated INDs, and guided development post-transition.
Impact for the client:
- Three INDs advanced successfully
- Zero FDA observations during audit
- Development continued without disruption
